Business Insider

Pacira BioSciences Announces Validation of EXPAREL Marketing Authorization Application from European Medicines Agency

-- Advances global expansion strategy to minimize postsurgical opioid use worldwide -- PARSIPPANY, N.J., June 25, 2019 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (“Pacira”) (NASDAQ: PCRX) today ...
Seeking Alpha

Pacira Announces FDA Acceptance of sNDA for Exparel Nerve Blocks to Produce Regional Analgesia in Lower Extremity Procedures

TAMPA, Fla., March 29, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced ...
Business Insider

Pacira Receives Positive CHMP Opinion for EXPAREL® (bupivacaine liposome injectable suspension) for the Treatment of Postsurgical Pain

-- CHMP opinion supported by four pivotal studies showing EXPAREL reduced pain scores and opioid use following surgery -- -- European Commission decision on the Marketing Authorization Application ...
Seeking Alpha

Pacira Announces Publication of Pivotal Study of EXPAREL as a Sciatic Nerve Block in the Popliteal Fossa for Patients After Bunionectomy

TAMPA, Fla., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (PCRX),, the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced ...
WHNT

Pacira Announces FDA Approval of Expanded EXPAREL Label to Include Two Additional Nerve Block Indications

— EXPAREL is the only FDA-approved single-dose regional analgesic to safely demonstrate four days of superiority versus bupivacaine in two clinical studies — — New indications for use as an adductor ...